(Press-News.org) NEW YORK, November, 17, 2010 — An international, multi-center study has revealed the discovery of a novel oncogene that is associated with uveal melanoma, the most common form of eye cancer. Researchers have isolated an oncogene called GNA11 and have found that it is present in more than 40 percent of tumor samples taken from patients with uveal melanoma. The findings are being published early online November 17, 2010 in the New England Journal of Medicine and will appear in the December 2, 2010, print issue.
"These findings are significant because we now have a much better understanding of the precise mechanism of this disease, which may yield targets and treatments in the future, said Boris C. Bastian, MD, PhD, Chair of the Department of Pathology at Memorial Sloan-Kettering Cancer Center and senior author of the study. "Currently, once this type of melanoma has spread beyond the eye, therapeutic options are extremely limited," added Dr. Bastian.
The eye is the second most common site in the body for melanomas, after the skin. There are about 1,500 people diagnosed with melanoma of the eye in the US each year. Most frequently, melanomas of the eye occur in the part of the eye known as the uveal tract—the vascular layer that includes the iris (the pigmented cells surrounding the pupil), the ciliary body (the ring-shaped muscle that changes the size of the pupil and the shape of the lens when the eye focuses), and the choroid (the pigmented layer under the retina). Most patients with melanoma of the eye experience no symptoms until the tumor has become large enough to cause vision problems. In this study, DNA was extracted from tumor samples of patients and genetic sequencing was performed. To validate this new oncogene, immunocompromised mice were injected with cells engineered to harbor the mutated genes and monitored for the formation of tumors.
Previous studies from this group have revealed another oncogene associated with uveal melanoma, called GNAQ. Prior to the discovery of GNAQ and GNA11, genetic mutations responsible for uveal melanoma were completely unknown. Based on this latest research and recent studies, 83 percent of uveal melanomas are now known to have an active mutation in the GNAQ or GNA11 oncogenes.
In addition, said Dr. Bastian, "since the large majority of uveal melanomas harbor mutations in these two oncogenes, this suggests that the activation of the Gq/11 pathway is the main route to the development of uveal melanoma and identifies a brand new target for therapeutic intervention."
###Researchers from the University of British Columbia, the University of California, San Francisco and the Medical University of Graz, in Austria collaborated on this work. Financial support was provided by the NIH, the Melanoma Research Alliance, the Canadian Institutes of Health, the Canadian Cancer Society, the European Commission, and the Jubilaeumsfonds of the Oesterreichische Nationalbank.
Memorial Sloan-Kettering Cancer Center is the world's oldest and largest private institution devoted to prevention, patient care, research, and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose, and treat cancer. These specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide. For more information, go to www.mskcc.org.
END
Left ventricular non-compaction (LVNC), a cardiomyopathy about which little is fully understood, is associated with heart failure (HF), stroke and ventricular arrhythmias, according to a study to be presented Nov. 17 at the 2010 American Heart Association (AHA) Scientific Sessions in Chicago. The researchers also will report that advanced imaging technologies reveal that developing these cardiac risks appear to progress over time in patients with LVNC.
LVNC is an inherited heart muscle condition in which the muscular wall of the left ventricle appears to be spongy and ...
Stop using racial profiling, says Professor William Press from the University of Texas at Austin. He claims that as well as being politically and ethically questionable, racial profiling does no better in helping law enforcement officials in their task of catching terrorists than standard uniform random sampling techniques. This is the topic of a paper publishing today in Significance, the magazine of the Royal Statistical Society and the American Statistical Association.
Racial profiling rests on the idea that people from particular racial or ethnic groups are more ...
Northwestern Medicine physician researchers are revolutionizing treatment of cardiovascular disease by utilizing patients' own stem cells to regenerate heart and vascular tissue. Northwestern Medicine is the lead site for a study examining stem cell transplantation as treatment for critical limb ischemia. Chief investigator Douglas Losordo, MD, director of the Program in Cardiovascular Regenerative Medicine at Northwestern Memorial Hospital and the Eileen M. Foell Professor of Heart Research of Northwestern University's Feinberg School of Medicine, will present the findings ...
PASADENA, Calif. — Researchers at the California Institute of Technology (Caltech) have demonstrated quantum entanglement for a quantum state stored in four spatially distinct atomic memories.
Their work, described in the November 18 issue of the journal Nature, also demonstrated a quantum interface between the atomic memories—which represent something akin to a computer "hard drive" for entanglement—and four beams of light, thereby enabling the four-fold entanglement to be distributed by photons across quantum networks. The research represents an important achievement ...
A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies.
Results of the phase II(a) clinical trial will be presented at the 22nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Berlin today (Thursday). The trial found that when the new drug, inecalcitol, was combined with the existing, current therapy (docetaxel and prednisone) 83% of patients responded to the treatment ...
Scientists in Germany have developed a way of smuggling an anti-cancer drug past the protective blood-brain barrier and into brain tumours and metastases using a nanocarrier – a tiny capsule specially designed to pass through cell membranes and deliver its anti-cancer drug to the cancer cell.
The blood-brain barrier is formed by a network of closely sealed endothelial cells in the brain's capillaries, and it expresses a high level of proteins that pump foreign molecules away from the brain, while allowing others (such as glucose and insulin) that are necessary to the ...
In the movie Angels and Demons, scientists have solved one of the most perplexing scientific problems: the capture and storage of antimatter. In real life, trapping atomic antimatter has never been accomplished, until now.
A team made up of researchers from the University of Calgary, institutions across Canada and around the world have discovered how to trap atomic antimatter and the results of their discovery is published in the journal Nature.
"This is a major discovery. It could enable experiments that result in dramatic changes to the current view of fundamental ...
A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans. Some patients with a range of solid tumours, many of whom had been treated unsuccessfully for their cancer with other therapies, have seen their tumours shrink or stabilise for periods of between 46 days to more than a year. The research will be presented at the 22nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Berlin today (Thursday).
Laboratory studies of the drug, MK-4827, ...
WHAT:
In a review article appearing in the New England Journal of Medicine, scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, examine research under way to address the limitations of currently available influenza vaccines and develop more efficient and reliable strategies to make vaccines to protect against seasonal as well as pandemic influenza. Although licensed seasonal flu vaccines safely and effectively protect most people who receive them from illness and death, the degree of protection varies ...
Scientists at Emory University and the University of St. Andrews have solved the structure of a key protein from Lassa virus, which is endemic to West Africa and can cause a deadly hemorrhagic fever.
The structure reveals how the virus evades its host's immune system, and how it hijacks infected cells' vital machinery in a process scientists call "cap-stealing." Details of the structure could guide future efforts at antiviral drug discovery and vaccine development.
The results are published in this week's issue of Nature.
Lassa virus represents a family of viruses ...
